El-Ghitany Engy Mohamed, Hashish Mona H, Farag Shehata, Omran Eman A, Farghaly Azza Galal, Azzam Nashwa Fawzy Abd El-Moez
Department of Tropical Health, High Institute of Public Health, Alexandria University, Alexandria 21526, Egypt.
Department of Microbiology, High Institute of Public Health, Alexandria University, Alexandria 21526, Egypt.
Vaccines (Basel). 2022 Jan 22;10(2):174. doi: 10.3390/vaccines10020174.
Understanding the factors affecting humoral immune response to COVID-19 vaccines among healthcare workers (HCWs) is essential to predict their level of protection. Vaccination elicits antibodies against SARS-CoV-2 spike protein (anti-S).
To investigate the factors associated with the presence of SARS-CoV-2 anti-S antibodies among vaccinated HCWs.
This cross-sectional study included 143 vaccinated HCWs, with or without a history of previous COVID-19 infection (clinically, radiologically, or by laboratory results) from different departments. Socio-demographic, clinical, as well as vaccine-related data, were recorded. Serum samples were collected and tested for SARS-CoV-2 spike antibodies.
Vaccination provoked an immunogenic response, where the overall anti-S positivity was 83.9% (95% CI: 77.8-90.0%). The response was not affected either by the age or gender of HCWs. Out of the 143 HCWs, 46 (32.1%; 95% CI: 24.4-39.9%) reported a previous history of COVID-19 infection, and seropositivity was significantly higher among them ( = 0.002), and it was associated with the frequency of infection ( = 0.044) and duration since diagnosis of COVID-19 infection ( = 0.065). They had higher median anti-S titers (111.8 RU/mL) than those without infection (39.8 RU/mL). Higher seropositivity was observed with Oxford/AstraZeneca vaccine (AZD1222) (88.9%; 95% CI: 83.1-95.0%) than Sinopharm (BBIBP-CorV) (67.7%; 95% CI: 50.3-85.2%), and with receiving two doses of vaccine (92.3%; 95% CI: 87.1-97.5%).
Antibody positivity was significantly affected by the previous history of COVID-19 infection, type of vaccine, the number of doses received, and duration since vaccination.
了解影响医护人员对新冠疫苗体液免疫反应的因素对于预测其保护水平至关重要。接种疫苗可引发针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的抗体(抗S)。
调查接种疫苗的医护人员中与SARS-CoV-2抗S抗体存在相关的因素。
这项横断面研究纳入了143名接种疫苗的医护人员,他们来自不同科室,有或无既往新冠病毒感染史(临床、影像学或实验室检查结果)。记录社会人口学、临床以及与疫苗相关的数据。采集血清样本并检测SARS-CoV-2刺突抗体。
接种疫苗引发了免疫反应,总体抗S阳性率为83.9%(95%置信区间:77.8 - 90.0%)。该反应不受医护人员年龄或性别的影响。在143名医护人员中,46人(32.1%;95%置信区间:24.4 - 39.9%)报告有既往新冠病毒感染史,他们的血清阳性率显著更高(P = 0.(此处原文有误,推测为= 0.002)),且与感染频率(P = 0.044)和自新冠病毒感染诊断后的持续时间(P = 0.065)相关。他们的抗S滴度中位数(111.8 RU/mL)高于未感染的医护人员(39.8 RU/mL)。观察到牛津/阿斯利康疫苗(AZD1222)的血清阳性率(88.9%;95%置信区间:83.1 - 95.0%)高于国药集团疫苗(BBIBP-CorV)(67.7%;95%置信区间:50.3 - 85.2%),且接种两剂疫苗的血清阳性率(92.3%;95%置信区间:87.1 - 97.5%)更高。
抗体阳性率受既往新冠病毒感染史、疫苗类型、接种剂量数以及接种后的持续时间显著影响。